ReviewJournal of psychopharmacology (Oxford, England)2013
A review of anti-inflammatory agents for symptoms of schizophrenia.
Review in Journal of psychopharmacology (Oxford, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 4 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis.The international journal of neuropsychopharmacology · 2017Pooled it
- A significant causal association between C-reactive protein levels and schizophrenia.Scientific reports · 2016Pooled it
- Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness.Psychopharmacology · 2016Pooled it
- Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials.Schizophrenia bulletin · 2013Pooled it
- Immune-neuroendocrine crosstalk in mood and psychotic disorders: A meta-analysis and systematic review.Brain, behavior, & immunity - health · 2025Review
- Whole-exome sequencing of individuals from an isolated population under extreme conditions implicates rare risk variants of schizophrenia.Translational psychiatry · 2024Article
- Extracellular Vesicles in Mental Disorders: A State-of-art Review.International journal of biological sciences · 2023Review
- The Strategy of Targeting Peroxisome Proliferator-Activated Receptor (PPAR) in the Treatment of Neuropsychiatric Disorders.Advances in experimental medicine and biology · 2023Article
- Functional Nutrition as Integrated Intervention for In- and Outpatient with Schizophrenia.Current neuropharmacology · 2023Article
- Current State of Fluid Lipid Biomarkers for Personalized Diagnostics and Therapeutics in Schizophrenia Spectrum Disorders and Related Psychoses: A Narrative Review.Frontiers in psychiatry · 2022Review
- Fibroblast Growth Factor 9 as a Potential Biomarker for Schizophrenia.Frontiers in psychiatry · 2022Article
- Mechanisms underlying dorsolateral prefrontal cortex contributions to cognitive dysfunction in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Review
- Update on Statin Treatment in Patients with Neuropsychiatric Disorders.Life (Basel, Switzerland) · 2021Review
- Olanzapine Induces Inflammation and Immune Response via Activating ER Stress in the Rat Prefrontal Cortex.Current medical science · 2021Article
- Transcriptomic Data Analysis Reveals a Down-Expression ofBrain sciences · 2021Article
- Naturally Inspired Pyrimidines Analogues for Alzheimer's Disease.Current neuropharmacology · 2021Review
- Concordance of Immune-Related Markers in Lymphocytes and Prefrontal Cortex in Schizophrenia.Schizophrenia bulletin open · 2021Article
- Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders.Molecules (Basel, Switzerland) · 2020Review
- Inflammation in Mental Disorders: Is the Microbiota the Missing Link?Neuroscience bulletin · 2020Review
- Serum galectin-3 levels are decreased in schizophrenia.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Schizophrenia is a chronic debilitating mental disorder that affects about 1% of the US population. The pathophysiology and etiology remain unknown, thus new treatment targets have been challenging and few novel treatments with new mechanisms of action have come to market in the past few decades. Increasing attention has been paid to the role of inflammation in schizophrenia and new data suggests that decreasing inflammation and inflammatory biomarkers may play some role in schizophrenia treatment. This review summarizes the clinical trial literature regarding medications that possess anti-inflammatory properties that have been tested for schizophrenia symptoms and covers such medications as non-steroidal anti-inflammatory agents, such as the cyclo-oxygenase-2 (COX-2) inhibitors and aspirin, omega-3 fatty acids, neurosteroids and minocycline. Overall, there is accumulating evidence, albeit mostly adjunctive treatments, that agents working on inflammatory pathways have some benefits in people with schizophrenia. In the next few years the field will begin to see data on many treatments with anti-inflammatory properties that are currently under study. Hopefully advancements in understanding inflammation and effective treatments having anti-inflammatory properties may help revolutionize our understanding and provide new targets for prevention and treatment in schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.